Yuquan Wang
About Yuquan Wang
Yuquan Wang, 53, serves as a Director of FutureTech II Acquisition Corp. (FTII). He has been on the board since the company’s inception and previously served as FTII’s Chief Executive Officer until August 2023; he is the founding partner of Haiyin Capital and currently CEO and director of FutureTech Acquisition Corp. His background spans venture investing and multiple board roles in technology and healthcare-related enterprises, with extensive cross-border advisory experience.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| FutureTech II Acquisition Corp. (FTII) | Chief Executive Officer | Inception – Aug 2023 | Founding leadership of SPAC platform; transitioned to Director role |
| Soft Robotics Inc. | Board Member | Feb 2016 – Jan 2021 | Robotics commercialization oversight |
| Wicab, Inc. | Board Member | Since Jul 2014 | Neurotech/medical devices board participation |
| Cerevast Medical, Inc. | Board Member | Since Oct 2014 | Medtech strategic guidance |
| Frost & Sullivan (Beijing) | Board Member | Since Jan 2003 | Advisory/market research governance |
| T4Game | Board Member | Since Aug 2013 | Gaming industry oversight |
| Hanson Robotics | Board Member | Since Mar 2015 | AI/robotics governance |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Haiyin Capital | Founding Partner | Since Jan 2009 | Venture investing; cross-border tech focus |
| Innovation Map | Co-founder & Chairman | Since Jun 2016 | Innovation ecosystem leadership |
| Innovation Map USA | Chairman | Since Aug 2017 | U.S. innovation initiatives |
| George H.W. Bush Foundation for U.S.-China Relations | Advisor | Since Jan 2021 | U.S.-China policy advisory |
| Easescent Wine | Board Member | Since May 2009 | Consumer goods board role |
| Fuwen Enterprise Management Consulting | Board Member | Since Dec 2011 | Corporate advisory governance |
| Guangkong Haiyin Enterprise Management | Board Member | Since Oct 2014 | Enterprise management oversight |
| FutureTech Acquisition Corp. | CEO & Director | Current | SPAC leadership; potential interlocks with FTII |
Board Governance
- Independence: FTII’s board determined Neil Bush, Jonathan McKeage, and Jeffrey Moseley are independent; Yuquan Wang is not classified as an independent director.
- Classified board structure: Three classes; Wang is in the third class with Ray Chen; his term expires at the third annual meeting following Nasdaq listing cadence.
- Committee assignments: Wang is not listed on the Audit or Compensation committees. Audit Committee members: Neil Bush and Jeffrey Moseley; Chair: Jonathan McKeage; Compensation Committee members: Jonathan McKeage and Jeffrey Moseley; Chair: Jeffrey Moseley.
- Nominating/governance: No standing nominating committee; independent directors handle nominations; intent to form committee as required by law/Nasdaq.
- Independent director sessions: Independent directors will have regularly scheduled meetings.
- Attendance: No director meeting attendance rates disclosed in the proxy.
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer (Director) | None (pre-business combination) | SPAC policy: no cash compensation to officers/directors before de-SPAC |
| Committee membership fees | None (pre-business combination) | No committee cash fees prior to business combination |
| Committee chair fees | None (pre-business combination) | No chair cash fees prior to business combination |
| Meeting fees | None (pre-business combination) | Not paid prior to business combination |
| Reimbursement of expenses | Allowed | Audit committee reviews such payments quarterly |
| Administrative support fee | $10,000/month to affiliate of Sponsor (not a director fee) | For office space/utilities; ceases at de-SPAC or liquidation |
Performance Compensation
| Component | Grant Details | Vesting | Performance Metrics |
|---|---|---|---|
| Equity awards (RSUs/PSUs/options) | None prior to business combination | N/A | None disclosed |
| Post-combination incentives | To be set by independent comp committee or majority of independent directors | TBD post-de-SPAC | Not disclosed at SPAC stage |
Other Directorships & Interlocks
| Company/Organization | Role | Public Company? | Potential Interlock/Conflict Consideration |
|---|---|---|---|
| FutureTech Acquisition Corp. | CEO & Director | Not specified | SPAC-to-SPAC leadership may create target selection conflicts across platforms |
| Soft Robotics Inc. | Board Member (2016–2021) | Not specified | Prior robotics board links |
| Wicab, Inc.; Cerevast Medical, Inc.; Frost & Sullivan (Beijing); T4Game; Hanson Robotics; Easescent Wine; Fuwen Enterprise Mgmt; Guangkong Haiyin Enterprise Mgmt | Board/Advisor roles | Not specified | Network breadth; related-party oversight reviewed by Audit Committee per charter |
Expertise & Qualifications
- Founding partner of Haiyin Capital, with venture investing and innovation ecosystem leadership (Innovation Map/Innovation Map USA).
- Multiple board roles across robotics, gaming, medtech, and advisory organizations, indicating technology and cross-border experience.
- Advisor to a U.S.-China relations foundation, suggesting geopolitical and international engagement expertise.
Equity Ownership
| Holder | Class A Beneficially Owned | % of Class A | Class B Beneficially Owned | % of Class B | Approx. % of Outstanding | Record Date |
|---|---|---|---|---|---|---|
| Yuquan Wang | — | — | — | — | — | July 11, 2025 |
Note: Proxy table shows no Class A or Class B beneficial ownership for Yuquan Wang as of the record date.
Insider Trades
| Filing Type | Date | Notes |
|---|---|---|
| Form 4 (late filing) | Not specified | Proxy discloses one late Form 4 by Yuquan Wang in the preceding year. |
Governance Assessment
- Committee roles and independence: Wang is not on Audit or Compensation committees, and is not classified as independent; this reduces direct influence on financial reporting/compensation but raises independence concerns for board effectiveness.
- Classified board and Sponsor control: Prior to business combination, vacancies can be filled and directors removed by majority of founder shares; this concentrates control and may limit minority shareholder influence.
- Compensation transparency: No director cash or equity compensation prior to de-SPAC; expense reimbursements reviewed quarterly by Audit Committee; post-combination director/consulting fees may be paid but are not quantified at the SPAC stage.
- Ownership alignment: No disclosed beneficial ownership by Wang; combined with non-independence and prior CEO role, alignment relies on Sponsor incentives rather than personal shareholding.
- Related-party exposure and conflicts: Significant Sponsor Extension Loans and Working Capital Loans (non-interest-bearing, convertible) benefit from deal completion; board explicitly discloses Sponsor/director/officer incentives to complete a business combination over liquidation—classic SPAC conflict profile.
- Nominating/governance processes: No standing nominating committee; independent directors manage nominations, with intention to form committee as required; could be adequate but less formalized than peers.
- Compliance signals: One late Form 4 for Wang noted; isolated but a negative governance datapoint for reporting timeliness.
RED FLAGS
- Not independent; previously CEO of FTII, now a Director, which can impair objective oversight.
- Multi-SPAC leadership (CEO/director of FutureTech Acquisition Corp.) introduces potential target-selection conflicts across SPAC vehicles.
- Sponsor loans/extension payments create strong incentives to consummate a deal; board acknowledges differentiated interests vs. public shareholders.
- Late Section 16 Form 4 filing by Wang.
Positives
- Audit Committee includes an “audit committee financial expert” (McKeage) and is composed of independent directors.
- Compensation Committee composed entirely of independent directors; may retain independent advisors with required independence assessments.
- Code of Ethics in place; related-party transactions require Audit Committee review pre-entry.
Compensation Committee Analysis
- Members: Jonathan McKeage (member), Jeffrey Moseley (member, Chair). Both are independent.
- Authority: May engage compensation consultants/counsel subject to independence evaluations per Nasdaq/SEC rules; responsible for remuneration frameworks, if any, and director compensation recommendations.
- Interlocks: No compensation committee interlocks or insider participation disclosed.
Overall implication: Wang’s governance profile reflects typical SPAC sponsor-centric incentives, low personal share ownership alignment, and non-independence, offset by independent oversight in Audit and Compensation committees and formal ethics/related-party review structures. Investors should monitor de-SPAC negotiations for conflicts management, disclosure quality, and any post-combination consulting/compensation arrangements.